Global Amyotrophic lateral sclerosis (ALS) Market Insights Forecasts to 2030
- The Amyotrophic Lateral Sclerosis (ALS) market was valued at USD 651.10 Million in 2021.
- The Market is growing at a CAGR of 6.2% from 2022 to 2030
- The Global Amyotrophic Lateral Sclerosis (ALS) Market is expected to reach USD 901.70 Million by 2030
- Asia Pacific is expected to grow the fastest during the forecast period
Get more details on this report -
The global Amyotrophic Lateral Sclerosis (ALS) Market is expected to reach USD 901.70 Million by 2030, at a CAGR of 6.2% during the forecast period 2022 to 2030.
Amyotrophic lateral sclerosis (ALS) is sometimes known as Lou Gehrig's disease. It is a degenerative neurological disease in which nerve cells in the nervous system that regulate voluntary muscles are damaged. The condition is frequently characterised by twitching, stiffness, and weakness of the arms and hands as a result of muscle loss. The most common kind of motor neuron disease is ALS, which impairs the brain's ability to control voluntary movements by causing the body's cells to degenerate and die. In nearly half of ALS cases, patients lose their ability to swallow, inhale, communicate, walk, and use their hands. Within three to five years of progressive paralysis, persons with ALS frequently pass away from respiratory failure, according to the National Institute of Neurological Disorders and Stroke (NINDS).
Men are more likely to get amyotrophic lateral sclerosis than women. The defects brought on by both genetic inheritance and gene mutation have the potential to trigger the release of glutamate, which can further harm the motor neurons that regulate voluntary muscles. ALS patients frequently experience cramping, stiffness, muscular weakness, breathing issues, and fasciculation. Patients with amyotrophic lateral sclerosis have a higher mortality rate, which affects people's respiratory cycles by impairing breathing. The diaphragm's functionality and the chest muscles both suffer with ALS. Your bladder control and other senses are unaffected by ALS.
This research report categorizes the market for Amyotrophic lateral sclerosis (ALS) market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Amyotrophic lateral sclerosis (ALS) market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Amyotrophic lateral sclerosis (ALS) market.
Global Amyotrophic lateral Sclerosis (ALS) Market Report Coverage
|Market Size in 2021:||USD 651.10 Million|
|Forecast Period 2021-2030 CAGR:||6.2%|
|2030 Value Projection:||USD 901.70 Million|
|Historical Data for:||2017-2020|
|No. of Pages:||190|
|Tables, Charts & Figures:||130|
|Segments covered:||By Treatment, By Distribution Channel, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi ,Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, ADVANZ PHARMA|
|Pitfalls & Challenges:||Covid-19 Impact Analysis|
Get more details on this report -
The expansion of the market's growth will be significantly influenced by the rise in the prevalence of amyotrophic lateral sclerosis. The increasing cost of healthcare is another important factor affecting the market for amyotrophic lateral sclerosis (ALS). Also, the amyotrophic lateral sclerosis (ALS) industry will rise as a result of improvements in medical technology, increased awareness-raising efforts by both public and private organisations, and rising government support. The market for treatments for amyotrophic lateral sclerosis (ALS) will expand at a faster rate due to additional reasons such increased demand for efficient treatments and an ageing population. The market for amyotrophic lateral sclerosis (ALS) will also grow as a result of rising disposable income and a propensity for sedentary lifestyle.
Amyotrophic lateral sclerosis (ALS) market expansion will be constrained by the disease's consequences. Reduced awareness and a lack of technically qualified personnel will further threaten the business.
- In 2021, the Medication Segment is dominating the market with the largest market share over the forecast period.
On the basis of treatment, the global Amyotrophic lateral sclerosis (ALS) market is segmented into Medication, Physical Therapy, and Speech Therapy. Among these, the medication segment is dominating the market with the largest market share over the forecast period. Rlutek (riluzole) and Radicava are two FDA-approved medications for the condition (edaravone). Due to the growing desire for novel strategies and cutting-edge therapeutic options, steam cell therapies are also anticipated to experience significant expansion.
- In 2021, the Hospital Pharmacies segment holds the highest market share over the forecast period.
Based on the distribution channel, the Amyotrophic lateral sclerosis (ALS) Market is segmented into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment holds the highest market share over the forecast period. This market's expansion is aided by the need for numerous hospital stays and visits during ALS treatment. Both hospital pharmacy and retail pharmacies are highly preferred by patients. This can be attributed to the simple and quick access to a wide selection of medications and sufficient goods in the stock made available by these distribution channels.
Regional Segment Analysis of the Amyotrophic lateral sclerosis (ALS) Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share over the forecast period.
Get more details on this report -
The global market for the treatment of amyotrophic lateral sclerosis (ALS) is anticipated to be dominated by North America with a sizable proportion. Also, the presence of an ageing population makes these issues more prevalent. The majority of people over the age of 50 are more likely to develop this disorder, according to the Centers for Disease Control and Prevention (CDC) and the Organization for Toxic Substances and Disease Registry (ATSDR), which is expected to increase demand for therapies for amyotrophic lateral sclerosis in this region.
- In April 2020, To assist ALS patients in the greater San Diego area in participating in physical and mental wellness initiatives, IonisPharma launched a $25,000 award.
The report offers the appropriate analysis of the key organizations/companies involved within the global Amyotrophic lateral sclerosis (ALS) market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Orion Corporation
- Bausch Health Companies Inc.
- CYTOKINETICS, INC.
- Aquestive Therapeutics, Inc.
- Covis Pharma
- Sun Pharmaceuticals Industries Ltd
- Mitsubishi Tanabe Pharma Corporation
- BrainStorm Cell Limited
- ViroMed Co., Ltd
- Ionis Pharmaceuticals
- Genervon Biopharmaceuticals, LLC
- Orphazyme A/S
- Apotex Inc
- Neuralstem, Inc.
- Implicit Bioscience
- F. Hoffmann-La Roche Ltd
- AB Science
- ADVANZ PHARMA
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2021 to 2030. Spherical Insights has segmented the global Amyotrophic lateral sclerosis (ALS) market based on the below-mentioned segments:
Amyotrophic lateral sclerosis (ALS) Market, By Treatment
- Physical Therapy
- Speech Therapy
Amyotrophic lateral sclerosis (ALS) Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
Amyotrophic lateral sclerosis (ALS) Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?